United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - micrurus corallinus venom (unii: v0s6h36980) (micrurus corallinus venom - unii:v0s6h36980), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), arsenic triiodide (unii: 3029988o2t) (arsenic cation (3+) - unii:c96613f5av), gold (unii: 79y1949pyo) (gold - unii:79y1949pyo), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), selenicereus grandiflorus stem (unii: 7114sv0myk) (selenicereus grandiflor - micrurus corallinus venom 30 [hp_x] in 1 ml - hypertension     formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.                              formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - micrurus corallinus venom (unii: v0s6h36980) (micrurus corallinus venom - unii:v0s6h36980), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), arsenic triiodide (unii: 3029988o2t) (arsenic cation (3+) - unii:c96613f5av), gold (unii: 79y1949pyo) (gold - unii:79y1949pyo), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), selenicereus grandiflorus stem (unii: 7114sv0myk) (selenicereus grandiflor - micrurus corallinus venom 30 [hp_x] in 1 g - hypertension     formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.                              formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.

European Union - English - EMA (European Medicines Agency)

mylan s.a.s - ambrisentan - hypertension, pulmonary - antihypertensives, - ambrisentan mylan is indicated for the treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.ambrisentan mylan is indicated for the treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.   - macitentan - hypertension, pulmonary - antihypertensives, - opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease.

European Union - English - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

pfizer ltd. - sitaxentan sodium - hypertension, pulmonary - antihypertensives, - treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - ambrisentan - hypertension, pulmonary - antihypertensives, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.1).  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.1).

European Union - English - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). 

European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with world health organization (who) functional class iii. efficacy has been shown in:primary (idiopathic and familial) pah;pah secondary to scleroderma without significant interstitial pulmonary disease;pah associated with congenital systemic-to-pulmonary shunts and eisenmenger’s physiology.some improvements have also been shown in patients with pah who functional class ii.stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - antihypertensives, - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii.efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. , some improvements have also been shown in patients with pah who functional class ii. tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,